RBC maintains Angiotech at outperform

Angiotech Pharmaceuticals Inc. was kept at its outperform, speculative risk, rating and $14 price target by RBC Capital Markets analyst Douglas Miehm on news of the company's positive data from the European Vascular Wrap clinical trial of 109 patients. Over the next couple of months Angiotech will analyze the data and file for CE mark approval in the European Union, according to Miehm, with approval expected in mid-2007. Shares of the Vancouver, B.C.-based medical technology company were up 23 cents, or 2.70%, at $8.73. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.